GET DAILY SIGNALSRoivant Sciences (ROIV) Delivers Revenue Beat Driven by LISRAYA Launch
Key Takeaways
- Roivant Sciences reported fiscal second-quarter (ended September 30, 2026) revenue of $35.12 million, well above the roughly $4 million consensus, driven almost entirely by the first commercial sales of its newly approved drug LISRAYA.
- LISRAYA (brepocitinib), approved in August 2026 for dermatomyositis, generated $31.0 million in net product revenue during its first five weeks on the U.S. market.
- GAAP net loss per share was $0.27, better than the consensus loss of roughly $0.36 to $0.37.
- Net loss attributable to Roivant widened year over year to $191.6 million, partly reflecting $95.9 million in distributions tied to the Moderna patent settlement.
- The company ended the quarter with about $4.2 billion in cash, cash equivalents, and marketable securities, which management says supports a runway into profitability.
- Pipeline momentum continued, including a positive rheumatoid arthritis readout for IMVT-1402 and positive Phase 3 data for brepocitinib in non-infectious uveitis (NIU).
- For additional context, explore Major News, Today's Price Move, Price Targets, and Forecast on Tickeron's dedicated pages for this ticker.
- You can also discover data-driven trade ideas and market opportunities with Trending AI Robots.
Earnings Context and Why It Matters
Roivant Sciences' fiscal second-quarter report marks a pivotal transition for the company, which has historically been viewed as a clinical-stage pipeline story. With the August 2026 U.S. Food and Drug Administration (FDA) approval of LISRAYA for dermatomyositis, ROIV recorded its first meaningful product revenue, effectively becoming a commercial-stage biopharmaceutical business. For investors, this quarter offers the first concrete evidence of real-world demand for LISRAYA, alongside updates on a broad autoimmune and pulmonary pipeline. The results also matter because they arrive during a period of rapid pipeline catalysts, making the launch trajectory, spending discipline, and balance-sheet strength central to how the market values the company's long-term path toward profitability.
Reported Results
For its fiscal second quarter ended September 30, 2026, ROIV reported total revenue of $35.12 million, dramatically exceeding the consensus estimate of roughly $4 million. Nearly all of the top-line result came from $31.0 million in net product revenue for LISRAYA, a once-daily JAK and TYK2 inhibitor, during its first five weeks following August 2026 approval. The remaining revenue reflected license, milestone, and other income. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
On the bottom line, Roivant posted a GAAP net loss of $0.27 per share, better than the consensus loss of approximately $0.36 to $0.37. Net loss attributable to Roivant widened to $191.6 million, compared with $223.4 million a year earlier, partly due to $95.9 million in distributions related to Genevant equity awards participating in Moderna settlement proceeds. Roivant ended the quarter with about $4.2 billion in cash, cash equivalents, and marketable securities, and repurchased roughly $72.5 million of stock during the period.
Market Reaction and Investor Sentiment
Investor reaction to the fiscal second-quarter report was positive, with Roivant shares rising in pre-market trading after the results were announced. The scale of the revenue beat, driven by LISRAYA's early launch, signaled that the company's first commercial product is seeing genuine early prescriber and patient demand. However, sentiment carried some nuance. Management acknowledged that specialty-pharmacy stocking contributed to the $31.0 million figure and indicated a modest headwind is likely in the December quarter as that inventory normalizes. Additionally, the broader net loss widening, tied partly to one-time settlement-related distributions, tempered enthusiasm. Overall, the market interpreted the quarter as materially de-risking the story, even as questions remain about the durability and true underlying demand trajectory of the LISRAYA launch.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching several key factors. The most immediate is the durability of LISRAYA's commercial launch. Management signaled that the inventory and stocking dynamics that boosted the September quarter should normalize, creating a modest near-term headwind before becoming largely irrelevant next year. Tracking the pace of new patient starts, prescriber breadth, and payer dynamics will be central to evaluating whether the launch can scale.
Pipeline catalysts also remain a major focus. A supplemental New Drug Application (sNDA) for brepocitinib in non-infectious uveitis is expected in the first half of 2027, following positive Phase 3 data. The positive IMVT-1402 readout in difficult-to-treat rheumatoid arthritis adds another potentially registrational program to watch, alongside mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Finally, the balance sheet and capital allocation will be closely monitored. With roughly $4.2 billion in cash and an active share-repurchase program, Roivant has meaningful flexibility, while an additional $1.3 billion from the Moderna settlement remains contingent on a favorable resolution of a Section 1498 appeal. Together, these elements frame a forward story centered on commercial execution, clinical milestones, and disciplined use of capital.
Using Tickeron’s AI Screener in My Process
In my research on names like ROIV, I frequently turn to Tickeron’s AI Screener to filter for technical patterns, fundamentals, and AI-driven signals across biotech peers. It helps me quickly identify comparable trade ideas and market opportunities without manual effort, adding a useful data-driven layer to evaluating launch trajectories and pipeline momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ROIV turns positive, indicating new upward trend
ROIV saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In 74 of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ROIV's RSI Indicator exited the oversold zone, 18 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for ROIV just turned positive on October 21, 2026. Looking at past instances where ROIV's MACD turned positive, the stock continued to rise in 43 of 57 cases over the following month. The odds of a continued upward trend are 75%.
ROIV moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ROIV crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +6.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where ROIV advanced for three days, in 230 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ROIV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
ROIV broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ROIV entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.637) is normal, around the industry mean (3.498). ROIV has a moderately low P/E Ratio (-108.000) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. ROIV's P/S Ratio (3333.333) is slightly higher than the industry average of (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 7 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ROIV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement